➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Express Scripts
Colorcon
Harvard Business School
McKinsey

Last Updated: May 10, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR UBROGEPANT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Ubrogepant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02828020 Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting Allergan Phase 3 2016-07-01 This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.
NCT02867709 Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Recruiting Allergan Phase 3 2016-08-01 This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
NCT02873221 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine Enrolling by invitation Allergan Phase 3 2016-09-01 This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
NCT04179474 Safety, Tolerability & Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Recruiting Allergan Phase 1 2019-09-26 This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
NCT04492020 Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants Not yet recruiting Allergan Phase 3 2020-08-31 Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine Not yet recruiting Allergan Phase 1 2021-03-30 Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. This study will assess the drug to drug interaction between atogepant and ubrogepant and assess the safety of atogepant and ubrogepant, when given alone or in combination, in adult participants with migraine. Atogepant is an investigational (unapproved) drug for the preventative treatment of migraine. Ubrogepant is a drug approved for the acute treatment of migraine. Adult participants with a history of migraine will be enrolled. Approximately, 30 participants will be enrolled in the study in multiple sites in the United States. Participants will receive oral tablets of ubrogepant, followed be oral tablets of atogepant, followed by administration of oral tablets of atogepant and ubrogepant in combination. The study duration will be 30 days with a 7 day follow period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, telephone assessments, blood tests, checking for side effects, and clinician-rated assessments.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ubrogepant

Condition Name

Condition Name for Ubrogepant
Intervention Trials
Migraine, With or Without Aura 3
Migraine 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ubrogepant
Intervention Trials
Migraine Disorders 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ubrogepant

Trials by Country

Trials by Country for Ubrogepant
Location Trials
United States 140
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ubrogepant
Location Trials
Florida 5
Missouri 5
Washington 4
North Carolina 4
Ohio 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ubrogepant

Clinical Trial Phase

Clinical Trial Phase for Ubrogepant
Clinical Trial Phase Trials
Phase 3 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ubrogepant
Clinical Trial Phase Trials
Recruiting 3
Not yet recruiting 2
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ubrogepant

Sponsor Name

Sponsor Name for Ubrogepant
Sponsor Trials
Allergan 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ubrogepant
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Johnson and Johnson
Colorcon
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.